The United States of America, As Represented by the Secretary, Department of Health and Human Services

Wayne State University

Yale University

Advanced Refining Technologies LLC

Semmelweis University

Genesis Theranostix Korlatolt Felelossegu Tarsasag

Roberto Romero

Sonia S Hassan

Tinnakorn Chaiworapongsa

Adi L Tarca

Piya Chaemsaithong

Sujatha Kannan

Raghavendra S Navath

Kannan Rangaramanujam

Anupa R Menjoge

Cecelia A Radlowski

Jifei Jia

Gill M Malick

Gil G Mor

Bruno C Nesci

Xianghua Yu

Hui Dai

Donna Neale

Hamutal Meiri

Rangaramanujam M Kannan

Offer Erez

Nandor Than

Lami Yeo

Gustavo Eduardo Abella

Zoltan Papp

Ricardo Enrique Gayoso

Gabor Juhasz

Adrienna Katalin Kekesi

Zoltán Papp

Gábor JUHÁSZ

Kannan M Rangaramanujam

Nándor Than

Anupa Menjoge

Raghavendra Navath

Adrienna Katalin KÉKESI

Provided are systems and methods for assessing the presence or risk of obstetrical complications, particularly those related to an angiogenic and anti-angiogenic imbalance. Also provided are methods of treating an angiogenic and anti-angiogenic imbalance with water-soluble statins, such as pravastatin.

Systems and methods to identify and treat subjects at risk for obstetrical complications

Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMDH1 and/or PGAM1, as markers of true labor.

Kits and methods to distinguish false labor and true labor

A method and apparatus of examining fetal hearts includes obtaining ultrasound data of a fetal heart to generate fetal heart images, displaying different marked sample images of a fetal heart and at respective cardiac phases, each marking a different feature of a fetal heart at a respective marked location, and sequentially presenting one of the different marked sample images to a user along with one of the fetal heart images that is a similar view. As each of the different marked sample images is sequentially presented, a user is prompted to mark the different feature in a respective fetal heart image based on its marked location to create a plurality of marked fetal heart images, and a geometric model of the heart is generated based on the marked fetal heart images, from which fetal echocardiography views can be extracted. The fetal echocardiography views of the fetal heart are displayed.

Apparatus and method for fetal intelligent navigation echocardiography

Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16and 22week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.

Kits and methods for prediction and treatment of preeclampsia

Alumina support compositions comprising at least 0.1 wt % of silica are disclosed. The alumina support are characterized by a pore volume of greater than 0.60 cc/g, a median pore size ranging from about 70 to about 120, a pore size distribution such that at least 90% of the total pore volume falls within the range of about 20 to about 250, and a pore size distribution width of no less than about 40. Alumina compositions of the present invention exhibit a primary peak mode at a pore diameter less than the median pore diameter. Also provided are catalysts made from the alumina supports, and processes of preparing and using the supports and catalysts.

Silica containing alumina supports, catalysts made therefrom and processes using the same

Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 &#x3bc;m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 &#x3bc;m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.

Injectable dendrimer hydrogel nanoparticles

Biomarkers tests which can be used to predict a positive or negative risk of preeclampsia are described. More specifically, a panel of biomarkers including MMP-7 and gpIIbIIIa, described. The test is useful to predict preeclampsia when a biological sample is obtained between the 16th and 22nd week of pregnancy. Prediction later in pregnancy can be achieved by a combination of Siglec-6, Activin A, ALCAM, and/or FCN2.

Kits and methods to distinguish between false and true labor are provided. The kits and methods can utilize differences in abundance and/or differences in the rate of change in abundance of B7-H2, SORC2, TF, C1-Esterase Inhibitor, Ran, IMD-H1 and/or PGAM1, as markers of true labor.

Provided are systems and methods to identify subjects at risk for preterm labor and/or preterm birth. The systems and methods utilize biomarkers. Also provided are systems and methods for decreasing the risk of preterm labor by administering a treatment following a positive risk identification.

Systems and methods to predict risk for preterm labor and/or preterm birth

Disclosed are specific biomarkers that allow for early testing of preeclampsia/HELLP syndrome. Thus, a method is provided predicting preeclampsia in a pregnant woman. Also disclosed is a kit comprising means for assaying a sample from a pregnant woman for the concentrations of the specific biomarkers.

Biomarker test for prediction or early detection of preeclampsia and/or HELLP syndrome

A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer. A method of site-specific delivery of a therapeutically active agent, by attaching a therapeutically active agent to a PAMAM dendrimer or multiarm PEG polymer using a disulfide bond, administering the PAMAM dendrimer or multiarm PEG polymer to a patient in need of treatment, localizing the dendrimer or multiarm PEG polymer to a site in need of treatment, and releasing the therapeutically active agent at the site in need of treatment.

Dendrimer based nanodevices for therapeutic and imaging purposes

Growing community of inventors

Grosse Pointe, MI, United States of America

Roberto Romero